Profile data is unavailable for this security.
About the company
Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The Company's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.
- Revenue in CNY (TTM)711.46m
- Net income in CNY-370.90m
- Incorporated2003
- Employees1.17k
- LocationBio-Thera Solutions Ltd5F, Building A6, No.11 Kaiyuan Avenue, SGUANGZHOU 510530ChinaCHN
- Phone+86 2 032203528
- Fax+86 2 032203218
- Websitehttps://www.bio-thera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jinyu Bio-Technology Co Ltd | 1.58bn | 282.51m | 11.67bn | 1.65k | 40.26 | 2.06 | -- | 7.38 | 0.2588 | 0.2588 | 1.44 | 5.05 | 0.2365 | 2.06 | 1.98 | 956,543.20 | 4.09 | 4.82 | 4.79 | 5.68 | 57.97 | 58.78 | 17.28 | 19.91 | 3.33 | -- | 0.0043 | 36.41 | 4.55 | -3.37 | 34.63 | -17.77 | -12.92 | -25.56 |
| Joinn Laboratories China Co Ltd | 2.33bn | -62.99m | 11.70bn | 2.50k | -- | 1.57 | -- | 5.02 | -0.0862 | -0.0862 | 3.12 | 10.75 | 0.23 | 0.6906 | 8.14 | -- | -0.6856 | 8.99 | -0.8219 | 11.07 | 39.46 | 46.76 | -2.98 | 32.01 | 3.51 | 0.9996 | 0.0079 | 23.79 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 1.80bn | 514.80m | 11.82bn | 2.47k | 22.95 | 2.71 | -- | 6.57 | 1.18 | 1.18 | 4.11 | 9.95 | 0.36 | 2.68 | 6.66 | 727,792.60 | 10.31 | -- | 11.11 | -- | 39.78 | -- | 28.63 | -- | 5.51 | -- | 0.0551 | -- | -18.34 | -- | -23.51 | -- | -- | -- |
| Liaoning Chengda Biotechnology Co Ltd | 1.76bn | 420.34m | 11.85bn | 1.73k | 28.06 | 1.22 | -- | 6.73 | 1.01 | 1.01 | 4.26 | 23.41 | 0.1743 | 0.7061 | 1.61 | 1,016,911.00 | 4.16 | 10.63 | 4.27 | 11.01 | 81.48 | 85.74 | 23.87 | 39.56 | 20.80 | -- | 0.002 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
| Sansure Biotech Inc | 1.20bn | 384.73m | 11.85bn | 2.01k | 31.24 | 1.58 | -- | 9.85 | 0.6448 | 0.6448 | 2.06 | 12.77 | 0.1377 | 0.8274 | 1.41 | 599,646.90 | 4.14 | 26.74 | 4.69 | 30.97 | 74.82 | 67.47 | 30.06 | 42.01 | 7.94 | -- | 0.0589 | 22.40 | -84.39 | 27.12 | -81.22 | 121.89 | 64.08 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.73bn | 511.96m | 12.04bn | 2.55k | 23.46 | 1.53 | -- | 4.41 | 0.5447 | 0.5447 | 2.90 | 8.35 | 0.2186 | 1.58 | 0.8134 | 1,071,832.00 | 4.06 | 3.48 | 5.61 | 4.78 | 46.09 | 38.93 | 18.56 | 10.08 | 2.35 | -- | 0.2862 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.18bn | 208.25m | 12.11bn | 1.55k | 58.15 | 5.38 | -- | 10.25 | 0.9769 | 0.9769 | 5.54 | 10.55 | 0.3743 | 1.21 | 4.71 | 764,598.40 | 6.69 | 5.86 | 9.15 | 7.59 | 63.15 | 55.41 | 17.87 | 17.20 | 1.08 | 33.77 | 0.3356 | 27.59 | 58.69 | 32.24 | 26.20 | 29.99 | 27.32 | -- |
| Bio-Thera Solutions Ltd | 711.46m | -370.90m | 12.47bn | 1.17k | -- | 11.40 | -- | 17.53 | -0.8957 | -0.8957 | 1.72 | 2.64 | 0.3099 | 0.9439 | 6.06 | 609,647.70 | -16.15 | -23.62 | -23.70 | -30.81 | 71.41 | 79.76 | -52.13 | -106.72 | 0.8258 | -367.55 | 0.3515 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.26bn | 453.31m | 12.65bn | 2.88k | 27.91 | 3.23 | -- | 3.88 | 1.05 | 1.05 | 7.56 | 9.08 | 0.6482 | 5.87 | 11.13 | 1,130,851.00 | 9.26 | 10.82 | 11.03 | 13.47 | 42.87 | 41.18 | 14.29 | 14.08 | 5.18 | -- | 0.0729 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
Data as of May 17 2024. Currency figures normalised to Bio-Thera Solutions Ltd's reporting currency: Chinese Yuan Renminbi CNY
3.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2023 | 2.36m | 0.58% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2023 | 1.86m | 0.45% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2023 | 1.84m | 0.45% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2023 | 1.58m | 0.39% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 1.43m | 0.35% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 1.32m | 0.32% |
| E Fund Management Co., Ltd.as of 30 Jun 2023 | 1.26m | 0.31% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.02m | 0.25% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2023 | 814.17k | 0.20% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 476.47k | 0.12% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
